Drugs that contain Ethinyl Estradiol; Segesterone Acetate
1. Annovera patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10765628 | MAYNE PHARMA | Method of providing birth control |
Feb, 2039
(14 years from now) | |
| US10632066 | MAYNE PHARMA | Method of providing birth control |
Feb, 2039
(14 years from now) | |
| US10780047 | MAYNE PHARMA | Method of providing birth control |
Feb, 2039
(14 years from now) | |
| US10918649 | MAYNE PHARMA | System for providing birth control |
Jun, 2039
(15 years from now) | |
| US10925882 | MAYNE PHARMA | System for providing birth control |
Jun, 2039
(15 years from now) | |
| US11529308 | MAYNE PHARMA | System for providing birth control |
Jun, 2039
(15 years from now) | |
| US10940157 | MAYNE PHARMA | System for providing birth control |
Jun, 2039
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 10, 2023 |
NCE-1 date: 10 August, 2022
Market Authorisation Date: 10 August, 2018
Treatment: Method of contraception by inserting a vaginal system for up to 13 21/7-day (in/out) cycles, wherein efficacy requires the system cannot be out of the vagina for more than 2 cumulative hours in any su...
Dosage: RING;VAGINAL
More Information on Dosage
ANNOVERA family patents
